主页 > 医药科学 >
【medical-news】拜耳抗癌药索拉非尼升高血压
LONDON (Reuters) - Bayer AG and Onyx Pharmaceutical Inc.'s key cancer drug Nexavar significantly raises the risk of high blood pressure, U.S. researchers said on Tuesday.
Writing in the journal Lancet Oncology, the researchers said people taking the drug generically known as sorafenib should be closely monitored and treated for high blood pressure to prevent cardiovascular complications.
Nexavar -- one of Bayer's top drug hopes -- is already approved in Europe and the United States for kidney cancer, and is Onyx's only drug on the market.
"Early detection and effective management of hypertension might allow for safer use of this drug," Shenhong Wu of State University of New York, Stoney Brook and colleagues wrote. "Future studies will be needed to identify the mechanism and appropriate treatment of sorafenib-induced hypertension."
Representatives for the companies could not immediately be reached for comment.
In November, the U.S. Food and Drug Administration (FDA) approved Nexavar medicine to treat liver cancer in a move extending drug's reach.
Trial results last June also showed the drug was the first medicine to extend the life of patients with advanced liver cancer in a large study -- adding about three months to survival compared with a placebo.
Bayer has said it expects Nexavar to reach 1 billion euros in annual sales if it gets approvals for treatment of various cancer indications. In 2006 Nexavar sales hit 130 million euros.
Wu and colleagues said the risk of hypertension with the drug taken as a pill has so far been unclear because of the limited number of patients in previous trials.
They conducted a review called a meta-analysis of nine studies that included 4,599 patients and were published between January 2006 and July 2007.
They found patients treated with sorafenib have a 23 percent higher chance of having an increase in blood pressure than those not given the drug. The risk of developing a more severe form of high-blood pressure rose 6 percent.
Liver cancer kills more than 600,000 people globally each year and is currently treated with limited success using a mix of surgery, radiation and chemotherapy.
Nexavar is also being tested against several other types of cancer, including non-small cell lung cancer and breast cancer.
http://www.reuters.com/article/healthNews/idUSL217848920080122 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 Nexavar significantly boosts hypertension risk
拜耳抗癌药多吉美（索拉非尼）升高血压
LONDON (Reuters) - Bayer AG and Onyx Pharmaceutical Inc.'s key cancer drug Nexavar significantly raises the risk of high blood pressure, U.S. researchers said on Tuesday.
伦敦（路透社）美国的科学家在上周二公布了他们关于拜耳公司的一项主要的抗癌药品索拉非尼的研究结果：这种抗癌药物有显著的升高血压的风险。
Writing in the journal Lancet Oncology, the researchers said people taking the drug generically known as sorafenib should be closely monitored and treated for high blood pressure to prevent cardiovascular complications.
研究者们在《柳叶刀》中发表的文章说：服用索拉非尼的患者都应该密切的监测血压以防止心血管系统并发症的发生。
Nexavar -- one of Bayer's top drug hopes -- is already approved in Europe and the United States for kidney cancer, and is Onyx's only drug on the market.
索拉非尼作为拜耳公司的一项主要的支柱药品，已经在欧洲与美国市场被获准作为肾癌的治疗药物，同时也是Onyx唯一上市的药物。
"Early detection and effective management of hypertension might allow for safer use of this drug," Shenhong Wu of State University of New York, Stoney Brook and colleagues wrote. "Future studies will be needed to identify the mechanism and appropriate treatment of sorafenib-induced hypertension."
纽约州立大学的Shenhong Wu、 Stoney Brook以及他们的同事们在文章中写道：“早期的监测血压以及在血压升高时给与有效的处理对于安全使用该药物是十分必要的。还有许多更进一步的试验需要去做，比如索拉非尼升高血压的机制是什么，怎样更有效合理的治疗索拉非尼引起的血压升高。”
Representatives for the companies could not immediately be reached for comment.
由于还没有联系到公司的发言人，关于拜耳公司代表对于该研究的反应目前还不得而知。
In November, the U.S. Food and Drug Administration (FDA) approved Nexavar medicine to treat liver cancer in a move extending drug's reach.
在11月，FDA又批准了索拉非尼作为治疗肝癌的药物，使该药物的使用范围又得到了扩大。
Trial results last June also showed the drug was the first medicine to extend the life of patients with advanced liver cancer in a large study -- adding about three months to survival compared with a placebo.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-07-22 18:44
医学,生命科学网